DocDollars

Immedica Pharma Us, Inc.

PA · United States · Reporting entity ID 100001081885

Total reported 2019–2025
$15.4M
#384 of 2,960 reporting companies — 0% of all reported industry payments
$1.05M in general payments across 2,889 records, plus $14.4M in research funding across 1,813 records.

How it breaks down

General payments $1,045,886
Research funding $14,388,837

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Immedica Pharma Us, Inc. reported $15.4M to US doctors and teaching hospitals from 2019 to 2025, ranking #384 of 2,960 reporting companies. 93% of that was research funding and 7% general payments such as consulting, speaking, food and travel. 2,889 general payment records and 1,813 research records were filed.

Common questions about Immedica Pharma Us, Inc.

How much has Immedica Pharma Us, Inc. paid US doctors?

Immedica Pharma Us, Inc. reported $15,434,723 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,045,886 in general payments, $14,388,837 in research funding.

How does Immedica Pharma Us, Inc. rank among drug and device companies?

It ranks #384 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Immedica Pharma Us, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.